Table 3 Outcomes by therapy in occult with no classic CNV.

Therapy	Trial	No of treated eyes	No of placebo eyes	Proportion of eyes with <3 lines of visual acuity loss
PDT‐V	VIP Trial11	166	92	At 1 year: 49% treated v 45% placebo
				At 2 years: 45% treated v 32% placebo (p = 0.032)
Pegaptanib sodium	EOP1003 and 1004*	115	124	At 1 year: 66% treated (0.3 mg) v 64.5% placebo

*These data have not been published—values estimated from data on file at the FDA: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053B1_02_FDA‐Backgrounder.pdf.